Investors who purchased shares of the Medicis Pharmaceutical Corp (NYSE:MRX) prior to August 31, 2012, and currently hold any of those NYSE:MRX shares have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
On September 3, 2012, Valeant Pharmaceuticals International, Inc. and Medicis Pharmaceutical Corporation announced that they have entered into an agreement under which Valeant Pharmaceuticals International will acquire all of the outstanding common stock of Medicis Pharmaceutical Corporation for $44.00 per share in cash.
However, the plaintiff alleges that the deal undervalues the company and shortchanges investors. Indeed, at least one analyst has set the high target price for NYSE:MRX shares at $45.00 per share. In addition, Medicis Pharmaceutical’
Furthermore, so the plaintiff, the terms of the merger agreement include improper deal protection devices that preclude competing offers.
Those who are current investors in Medicis Pharmaceutical Corp (NYSE:MRX) and purchased their Medicis Pharmaceutical Corp shares prior to the announcement, have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.